After a rare embryo mix-up at Monash IVF’s Brisbane clinic, calls for national oversight in assisted reproductive treatment are gaining urgency. But the challenges aren’t just legal – they’re deeply human.
In late 2023, a Brisbane woman gave birth to a child who was not genetically related to her due to an embryo mix-up at Monash IVF’s Brisbane clinic. The error was discovered in February 2025 when the birth parents sought to transfer their remaining embryos to another provider, revealing an unexpected embryo in storage. An investigation confirmed that an embryo from a different patient had been mistakenly thawed and transferred.
Monash IVF has apologized, undertaken internal audits, and launched an independent investigation led by Fiona McLeod SC. The company has pledged to implement all recommendations from this ongoing investigation.
This incident has ignited legal and ethical debates over parenthood and custody rights in Australia. Under Queensland law, the woman who gives birth is recognized as the legal mother, which may complicate custody claims by the biological parents.
The mix-up has also spotlighted inconsistencies in Australia’s IVF regulations, prompting calls for a national framework to ensure uniform standards and prevent future mishaps.
Patchwork oversight in a national market
Australia’s fertility industry has grown rapidly over the past two decades, with around 100,000 assisted reproductive technology (ART) cycles performed in 2022 — the vast majority of the 108,913 total cycles reported across Australia and New Zealand. However, regulation of IVF remains largely a state-based affair, with varying rules and degrees of enforcement.
In Victoria, assisted reproductive treatment is governed by the Assisted Reproductive Treatment Act 2008, enforced by the Victorian Assisted Reproductive Treatment Authority (VARTA). VARTA sets out rigorous requirements for consent, recordkeeping, and the handling of gametes and embryos.
New South Wales, Queensland, and other states lack equivalent statutory regulators, relying instead on national accreditation bodies and professional standards. The Fertility Society of Australia and New Zealand (FSANZ) and its affiliated Reproductive Technology Accreditation Committee (RTAC) oversee accreditation across clinics nationwide, but these are industry-led frameworks, not government-enforced regimes.
Monash IVF, for its part, is accredited under RTAC standards. However, this accreditation has not insulated it from questions about how such a catastrophic error could have occurred – and who is accountable.
The federal vacuum
While Australia has national legislation around privacy, human tissue, and donor conception, it lacks an overarching federal framework governing ART. This regulatory vacuum has created a mismatch: IVF is a national service – increasingly commodified and commercial – but oversight has an inconsistent record.
The Therapeutic Goods Administration (TGA) plays a limited role, regulating the import and handling of human gametes. The Office of the Gene Technology Regulator (OGTR) governs genetic modification. However, when it comes to core clinical and ethical matters – who can access IVF, how records are kept, how errors are reported – it is largely up to the states and the industry itself.
The result? When something goes wrong, families enter a legal minefield. Under Queensland law, the woman who gave birth is the child’s legal mother. The biological parents are seeking court orders to gain parental responsibility – an emotionally and legally complex process with no precedent in Australian case law.
Across the ditch: a clearer framework
New Zealand takes a more centralized approach. Fertility services there are governed by the Human Assisted Reproductive Technology Act 2004, which established the Advisory Committee on Assisted Reproductive Technology (ACART) and the Ethics Committee on Assisted Reproductive Technology (ECART). These bodies advise on policy, set binding guidelines, and assess individual applications for non-standard procedures.
Importantly, New Zealand’s regulatory framework emphasizes transparency, public accountability, and ethics – with a strong role for the Ministry of Health.
While not immune to controversy, the centralized oversight has helped avoid the jurisdictional inconsistencies seen in Australia. Every fertility provider must meet national standards and report regularly. Consent procedures and record-keeping obligations are strictly monitored, with penalties for non-compliance.
UK and EU models of statutory oversight
The United Kingdom offers perhaps the most structured model. The Human Fertilisation and Embryology Authority (HFEA), established in 1991, is an independent statutory regulator. It licenses all fertility clinics, inspects their operations, and enforces strict rules on embryo storage, donor anonymity, and treatment eligibility.
The HFEA also maintains a centralized database tracking every IVF cycle, embryo, and donor across the UK. Patients can access their records decades later – a safeguard that has become increasingly important as donor-conceived individuals seek information about their origins.
In the European Union, as might be expected, the landscape is more varied. Countries like France, Germany, and Sweden have robust national regulation, with strict limits on embryo creation and storage. Others, like Spain and the Czech Republic, have more liberal laws – ones that attract fertility tourists from abroad. The European Society of Human Reproduction and Embryology (ESHRE) provides some professional cohesion, but enforcement is ultimately national.
At the extremes, countries like Italy and Austria ban certain IVF practices outright (e.g., embryo freezing, donor insemination for single women), while others – notably the U.S. – rely largely on state-level oversight and voluntary professional guidelines, with no binding federal regulation specific to IVF, leaving oversight to the states or the market.
Why regulate IVF at all?
IVF may be a medical procedure, but it is one where ethics, law, and biology intertwine. Regulatory frameworks exist to protect patients from exploitation, ensure the safety and identity of embryos and gametes, and clarify the rights of donors, parents, and offspring.
Without clear oversight, clinics may vary in how they label and handle genetic material. Patients may not fully understand their rights. And in rare – but devastating – instances like the Brisbane mix-up, families may be left without legal clarity or recourse.
As commercial providers grow in scale and sophistication, risks pile up accordingly. According to the latest national data from UNSW and the Fertility Society of Australia and New Zealand, more than 100,000 ART cycles were performed in 2022 – a figure that reflects long-term growth in the sector despite a slight year-on-year decline of 2.1% from 2021. Each step introduces new points of failure – and new ethical questions.
What’s changing – and what isn’t
In response to the Monash incident, Queensland’s health minister pledged to examine existing laws and explore tougher enforcement options. The state is reportedly considering a mandatory reporting regime for errors, alongside a requirement for clinics to undergo annual independent audits.
Nationally, Health Minister Mark Butler has requested advice on how federal coordination might be improved. However, no formal policy review has been launched at the federal level. For now, Australia remains without a unified national framework for assisted reproductive treatment – even as public attention sharpens and pressure mounts.
The Monash IVF case may be an outlier, but it underscores broader vulnerabilities in how the country regulates a growing, complex, and emotionally charged sector. For regulators, policymakers, and families alike, it poses a fundamental question: when life begins in a lab, how do we ensure the systems around it are just as carefully designed?
The answer may lie not in overhauling IVF itself, but in bringing clarity, consistency, and accountability to the laws that shape it.
